FDA guides Advaxis over ADXS-PSA clinical trials
In the pre-IND meeting, Advaxis has discussed its development plan for ADXS-PSA with the FDA. Based on FDA input, the planned toxicology studies will be completed on schedule
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.